HomeCompareBIESF vs BTI

BIESF vs BTI: Dividend Comparison 2026

BIESF yields 0.15% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BIESF wins by $37.3K in total portfolio value· pulled ahead in Year 9
10 years
BIESF
BIESF
● Live price
0.15%
Share price
$32.00
Annual div
$0.05
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$75.0K
Annual income
$32,334.90
Full BIESF calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — BIESF vs BTI

📍 BIESF pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBIESFBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BIESF + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BIESF pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BIESF
Annual income on $10K today (after 15% tax)
$12.37/yr
After 10yr DRIP, annual income (after tax)
$27,484.67/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, BIESF beats the other by $25,116.02/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BIESF + BTI for your $10,000?

BIESF: 50%BTI: 50%
100% BTI50/50100% BIESF
Portfolio after 10yr
$56.4K
Annual income
$17,560.77/yr
Blended yield
31.16%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

BIESF
No analyst data
Altman Z
2.2
Piotroski
4/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BIESF buys
0
BTI buys
0
No recent congressional trades found for BIESF or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBIESFBTI
Forward yield0.15%5.38%
Annual dividend / share$0.05$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%11.3%
Portfolio after 10y$75.0K$37.7K
Annual income after 10y$32,334.90$2,786.64
Total dividends collected$52.6K$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: BIESF vs BTI ($10,000, DRIP)

YearBIESF PortfolioBIESF Income/yrBTI PortfolioBTI Income/yrGap
1$10,729$29.12$11,299$598.92$570.00BTI
2$11,539$58.39$12,794$703.91$1.3KBTI
3$12,464$117.38$14,518$829.07$2.1KBTI
4$13,573$236.99$16,513$978.64$2.9KBTI
5$15,006$482.41$18,827$1,157.84$3.8KBTI
6$17,053$996.86$21,518$1,373.12$4.5KBTI
7$20,364$2,117.50$24,657$1,632.46$4.3KBTI
8$26,516$4,726.47$28,329$1,945.74$1.8KBTI
9← crossover$39,876$11,503.41$32,637$2,325.33+$7.2KBIESF
10$75,002$32,334.90$37,708$2,786.64+$37.3KBIESF

BIESF vs BTI: Complete Analysis 2026

BIESFStock

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.

Full BIESF Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this BIESF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BIESF vs SCHDBIESF vs JEPIBIESF vs OBIESF vs KOBIESF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.